chair's take: her2-targeted and other agents for gastric cancer
Published 4 years ago • 132 plays • Length 34:31Download video MP4
Download video MP3
Similar videos
-
59:18
optimizing novel her2-targeted therapies and other agents in gastric cancer care
-
1:07:30
personalizing gastric cancer care with her2-targeted and other novel therapies
-
1:18:52
her2-positive gastrointestinal cancers: new evidence and practical guidance with targeted agents
-
1:16:56
navigating the integration of trop2-targeted therapy in tnbc and hr , her2- breast cancer
-
1:38:56
taking aim at gi cancers with personalized her2 and other molecularly targeted therapies
-
2:38
her2 in gastric cancer
-
1:22:29
capitalizing on her2-targeted regimens to improve outcomes for gastric/gej cancers, crc, and btc
-
1:35:31
leveraging targeted therapies to improve outcomes across the continuum of her2 breast cancer
-
51:40
trop2-targeting adcs as new tools in the tnbc and hr /her2- breast cancer treatment arsenal
-
54:02
navigating shifts in the treatment landscape for metastatic her2-positive breast cancer
-
32:54
raising the bar in her2-positive breast cancer
-
51:24
her2 and her3 alterations as therapeutic targets of increasing significance in solid tumors
-
3:12
advances in her2-targeted therapies for gastric cancer
-
1:09:24
raising the bar in hr /her2- early breast cancer: cdk4 and 6 inhibitors
-
0:54
targeted treatment for gastric cancer beyond her2
-
1:02:48
expanding treatment options in er /her2- breast cancer: serds, serms, sercas, and more
-
31:39
chair’s take: review of the latest hcc therapy advancements
-
1:31:37
personalizing treatment decisions in her2-altered breast cancer
-
57:18
navigating the expanding treatment arsenal for er /her2- breast cancer